Combined Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy Imaging in the Diagnosis of Prostate Cancer: A Systematic Review and Meta-analysis

European Urology

Volumn 55, Issue 3, 2009, Pages 575-591

  Umbehr, Martin ^a   Bachmann, Lucas M ^a   Held, Ulrike ^a   Kessler, Thomas M ^a   Sulser, Tullio ^a   Weishaupt, Dominik ^a   Kurhanewicz, John ^b   Steurer, Johann ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Diagnosis; MR imaging and MR spectroscopy imaging; Prostate cancer

Indexed keywords

CANCER DIAGNOSIS; CANCER RISK; CLINICAL TRIAL; DATA EXTRACTION; DIAGNOSTIC ACCURACY; HISTOPATHOLOGY; HUMAN; INFORMATION PROCESSING; MEDICAL LITERATURE; META ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADIOLOGIST; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TUMOR BIOPSY;

HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PROSTATIC NEOPLASMS;

EID: 58849115858     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.10.019     Document Type: Review

References (54)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. Walsh P.C., DeWeese T.L., and Eisenberger M.A. Clinical practice. Localized prostate cancer. N Engl J Med 357 (2007) 2696-2705
3. National Cancer Institute. SEER cancer statistics review: surveillance, epidemiology, and end results. http://seer.cancer.gov/statfacts/html/prost_print.html. Accessed August 28, 2008.
4. Yancik R., and Ries L.A. Aging and cancer in America. Demographic and epidemiologic perspectives. Hematol Oncol Clin North Am 14 (2000) 17-23
5. Parkin D.M., Bray F.I., and Devesa S.S. Cancer burden in the year 2000: the global picture. Eur J Cancer 37 Suppl 8 (2001) S4-66
6. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per millilitre. N Engl J Med 350 (2004) 2239-2246
7. Djavan B., Milani S., and Remzi M. Prostate biopsy: who, how, and when. An update. Can J Urol 12 Suppl 1 (2005) 44-48 discussion 99-100
8. Amsellem-Ouazana D., Younes P., Conquy S., et al. Negative prostatic biopsies in patients with a high risk of prostate cancer: is the combination of endorectal MRI and magnetic resonance spectroscopy imaging (MRSI) a useful tool? A preliminary study. Eur Urol 47 (2005) 582-586
9. Norberg M., Egevad L., Holmberg L., Sparen P., Norlen B.J., and Busch C. The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology 50 (1997) 562-566
10. Presti Jr. J.C., Chang J.J., Bhargava V., and Shinohara K. The optimal systematic prostate biopsy scheme should include eight rather than six biopsies: results of a prospective clinical trial. J Urol 163 (2000) 163-166 discussion 6-7
11. Eichler K., Hempel S., Wilby J., Myers L., Bachmann L.M., and Kleijnen J. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol 175 (2006) 1605-1612
12. Irwig L., and Glasziou P. Cochrane Methods Group on Systematic Review of Screening and Diagnostic Tests: recommended methods (1996), Cochrane Collaboration, Oxford, UK
13. Casciani E., Polettini E., Bertini L., et al. Prostate cancer: evaluation with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiol Med (Torino) 108 (2004) 530-541
14. Casciani E., Polettini E., Bertini L., et al. Contribution of the MR spectroscopic imaging in the diagnosis of prostate cancer in the peripheral zone. Abdom Imaging 32 (2007) 796-802
15. Chrzan R., Urbanik A., Dobrowolski Z., and Lipczynski W. Morphological MRI and 3D proton spectroscopy using endorectal coil in the diagnostics of prostate cancer-preliminary experience. Polish J Radiology 71 (2006) 42-47
16. Costouros N.G., Coakley F.V., Westphalen A.C., et al. Diagnosis of prostate cancer in patients with an elevated prostate-specific antigen level: role of endorectal MRI and MR spectroscopic imaging. AJR 188 (2007) 812-816
17. Fütterer J.J., Heijmink S.W., Scheenen T.W., et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 241 (2006) 449-458
18. Fütterer J.J., Scheenen T.W., Heijmink S.W., et al. Standardized threshold approach using three-dimensional proton magnetic resonance spectroscopic imaging in prostate cancer localization of the entire prostate. Invest Radiol 42 (2007) 116-122
19. Goeb K., Engehausen D.G., Krause F.S., et al. MRI spectroscopy in screening of prostate cancer. Anticancer Res 27 (2007) 687-693
20. Hasumi M., Suzuki K., Taketomi A., et al. The combination of multi-voxel MR spectroscopy with MR imaging improve the diagnostic accuracy for localization of prostate cancer. Anticancer Res 23 (2003) 4223-4227
21. Jung J.A., Coakley F.V., Vigneron D.B., et al. Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. Radiology 233 (2004) 701-708
22. Kaji Y., Kurhanewicz J., Hricak H., et al. Localizing prostate cancer in the presence of postbiopsy changes on MR images: role of proton MR spectroscopic imaging. Radiology 206 (1998) 785-790
23. Kumar V., Jagannathan N.R., Kumar R., et al. Correlation between metabolite ratios and ADC values of prostate in men with increased PSA level. Magn Reson Imaging 24 (2006) 541-548
24. Manenti G., Squillaci E., Carlani M., Mancino S., Di Roma M., and Simonetti G. Magnetic resonance imaging of the prostate with spectroscopic imaging using a surface coil. Initial clinical experience. Radiol Med (Torino) 111 (2006) 22-32
25. Mueller-Lisse U.G., Vigneron D.B., Hricak H., et al. Localized prostate cancer: effect of hormone deprivation therapy measured by using combined three-dimensional 1H MR spectroscopy and MR imaging: clinicopathologic case-controlled study. Radiology 221 (2001) 380-390
26. Portalez D., Malavaud B., Herigault G., et al. Predicting prostate cancer with dynamic endorectal coil MR and proton spectroscopic MR imaging. J Radiol 85 (2004) 1999-2004
27. Prando A. Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: early experience: editorial comment. Int Braz J Urol 31 (2005) 494-496
28. Reinsberg S.A., Payne G.S., Riches S.F., et al. Combined use of diffusion-weighted MRI and 1H MR spectroscopy to increase accuracy in prostate cancer detection. AJR 188 (2007) 91-98
29. Scheidler J., Hricak H., Vigneron D.B., et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging-clinicopathologic study. Radiology 213 (1999) 473-480
30. Shi H., Wu L.B., Ding H.Y., et al. Prostate cancer: diagnostic value of dynamic contrast-enchanced MRI, diffusion weighted imaging and 3D (1)H-MR spectroscopy. Chinese J Radiology 40 (2006) 678-683
31. Shukla-Dave A., Hricak H., Kattan M.W., et al. The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis. BJU Int 99 (2007) 786-793
32. Squillaci E., Manenti G., Mancino S., et al. MR spectroscopy of prostate cancer: initial clinical experience. J Exp Clin Cancer Res 24 (2005) 523-530
33. Swanson M.G., Vigneron D.B., Tabatabai Z.L., et al. Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues. Magn Reson Med 50 (2003) 944-954
34. Testa C., Schiavina R., Lodi R., et al. Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT. Radiology 244 (2007) 797-806
35. Wefer A.E., Hricak H., Vigneron D.B., et al. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol 164 (2000) 400-404
36. Wetter A., Hubner F., Lehnert T., et al. Three-dimensional 1H-magnetic resonance spectroscopy of the prostate in clinical practice: technique and results in patients with elevated prostate-specific antigen and negative or no previous prostate biopsies. Eur Radiol 15 (2005) 645-652
37. Yuen J.S., Thng C.H., Tan P.H., et al. Endorectal magnetic resonance imaging and spectroscopy for the detection of tumour foci in men with prior negative transrectal ultrasound prostate biopsy. J Urol 171 (2004) 1482-1486
38. Bhatia C., Phongkitkarun S., Booranapitaksonti D., Kochakarn W., and Chaleumsanyakorn P. Diagnostic accuracy of MRI/MRSI for patients with persistently high PSA levels and negative TRUS-guided biopsy results. J Med Assoc Thai 90 (2007) 1391-1399
39. Chen M., Dang H.D., Wang J.Y., et al. Prostate cancer detection: comparison of T2-weighted imaging, diffusion-weighted imaging, proton magnetic resonance spectroscopic imaging, and the three techniques combined. Acta Radiol 49 (2008) 602-610
40. Cirillo S., Petracchini M., Della Monica P., et al. Value of endorectal MRI and MRS in patients with elevated prostate-specific antigen levels and previous negative biopsies to localize peripheral zone tumours. Clin Radiol 63 (2008) 871-879
41. Saito K., Kaminaga T., Muto S., et al. Clinical efficacy of proton magnetic resonance spectroscopy (1H-MRS) in the diagnosis of localized prostate cancer. Anticancer Res 28 (2008) 1899-1904
42. Shukla-Dave A., Hricak H., Moskowitz C., et al. Detection of prostate cancer with MR spectroscopic imaging: an expanded paradigm incorporating polyamines. Radiology 245 (2007) 499-506
43. Mazaheri Y., Shukla-Dave A., Hricak H., et al. Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging-correlation with pathologic findings. Radiology 246 (2008) 480-488
44. Scheenen T.W., Heijmink S.W., Roell S.A., et al. Three-dimensional proton MR spectroscopy of human prostate at 3T without endorectal coil: feasibility. Radiology 245 (2007) 507-516
45. Westphalen A.C., Coakley F.V., Qayyum A., et al. Peripheral zone prostate cancer: accuracy of different interpretative approaches with MR and MR spectroscopic imaging. Radiology. 246 (2008) 177-184
46. Lijmer J.G., Mol B.W., Heisterkamp S., et al. Empirical evidence of design-related bias in studies of diagnostic tests. JAMA 282 (1999) 1061-1066
47. Harbord R.M., Deeks J.J., Egger M., Whiting P., and Sterne J.A. A unification of models for meta-analysis of diagnostic accuracy studies. Biostatistics 8 (2007) 239-251
48. Zwinderman A.H., and Bossuyt P.M. We should not pool diagnostic likelihood ratios in systematic reviews. Stat Med 27 (2008) 687-697
49. Prando A., Kurhanewicz J., Borges A.P., Oliveira Jr. E.M., and Figueiredo E. Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: early experience. Radiology 236 (2005) 903-910
50. Qiang Y.Q., Guo Y.M., Wang P., et al. A meta-analysis for assessing the value of MR spectroscopy in the diagnosis of prostate cancer. J Med Colleges PLA 21 (2006) 401-407
51. Engelbrecht M.R., Jager G.J., Laheij R.J., Verbeek A.L., van Lier H.J., and Barentsz J.O. Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis. Eur Radiol 12 (2002) 2294-2302
52. Kirkham A.P.S., Emberton M., and Allen C. How good is MRI at detecting and characterising cancer within the prostate?. Eur Urol 50 (2006) 1163-1175 discussion 75
53. Shah N., Sattar A., Benanti M., Hollander S., and Cheuck L. Magnetic resonance spectroscopy as an imaging tool for cancer: a review of the literature. J Am Osteopath Assoc 106 (2006) 23-27
54. Bachmann LM, ter Riet G, Weber WE, Kessels AG. Multivariable adjustments counteract spectrum and test review bias in accuracy studies. J Clin Epidemiol. In press. doi:10.1016/j.jclinepi.2008.02.007.